all report title image
  • Published On : Aug 2022
  • Code : CMI5154
  • Industry : Pharmaceutical
  • Pages : 176
  • Formats :

ANCA Vasculitis is a type of autoimmune disease that causes vasculitis, swelling or inflammation of blood vessels. ANCA stands for Anti-Neutrophilic Cytoplasmic Autoantibody. ANCA vasculitis is an autoimmune disease affecting small blood vessels in the body. Neutrophils are a particular subset of white blood cells that are the target of ANCAs, autoantibodies causing the disease. They target the cytoplasm of neutrophils (the inside of the cell). Neutrophils attack the body's small blood vessels when ANCAs (the autoantibodies) adhere to them. This is how vasculitis, or blood vessel inflammation, develops in this condition.

Global ANCA vasculitis drug market is estimated to be valued at US$ 463.82 million in 2022 and is expected to exhibit a CAGR of 5.5% during the forecast period (2022-2030).

Figure 1.Global ANCA Vasculitis Drug Market Share (%), by Type, 2022

ANCA Vasculitis Drug  | Coherent Market Insights

Increasing approvals for ANCA vasculitis drugs by the regulatory bodies is expected to drive growth of the ANCA vasculitis drug market

Key players in market are focused on receiving approvals from the regulatory bodies for drugs used to treat ANCA vasculitis, which is expected to drive the market growth over the forecast period. For instance, in October 2021, ChemoCentryx, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA vasculitis), in combination with standard therapy.

CMI table icon

ANCA Vasculitis Drug Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 463.82 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 5.5% 2030 Value Projection: US$ 711.83 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Renal-limited Vasculitis
  • By Drug Type: Glucocorticoids, Cyclophosphamide, Rituximab, Methotrexate, Mycophenolate mofetil, Azathioprine, Mepolizumab, Avacopan, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies  
Companies covered:

ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen,  InflaRx GmbH, and AstraZeneca

Growth Drivers:
  • Increasing approvals for ANCA vasculitis drugs by the regulatory bodies
  • Increasing research and development activities by key players in market to develop ANCA vasculitis drugs
Restraints & Challenges:
  • Side effects associated with glucocorticoid use such as glucocorticoid toxicity

Figure 2.Global ANCA Vasculitis Drug Market Share (%), by Distribution Channel, 2022

ANCA Vasculitis Drug  | Coherent Market Insights

Increasing research and development activities by key players in market to develop ANCA vasculitis drugs are expected to drive the market growth during the forecast period.

Key players in market are focused on carrying out research and development activities for the development of ANCA vasculitis drugs, which is expected to drive the market growth over the forecast period. For instance, in November 2021, InflaRx N.V., a clinical-stage biopharmaceutical company, announced positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV). The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to standard of care, while significantly reducing the need for glucocorticoid (GC) treatment in this life-threatening indication

Global ANCA Vasculitis Drug Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another

The COVID-19 pandemic had a negative economic impact on the global ANCA vasculitis market, owing to the direct impact of the pandemic on not going to hospitals and undertaking laboratory and other tests. Higher density of immunosuppression (including prednisone use of more than 10 mg a day) was associated with a greater likelihood of avoiding tests or visits. For instance, according to an article published by the National Center for Biotechnology Information, in October 2021, an alarming number of patients (10.5%) stopped their immunosuppression, without consultation with their managing physician. Thus, the COVID-19 pandemic had a negative impact on the global ANCA vasculitis market.

Global ANCA Vasculitis Drug Market: Restraint

The major factors that hinder growth of the global ANCA vasculitis drug market include side effects associated with glucocorticoid use such as glucocorticoid toxicity. Higher doses of steroids in ANCA-associated vasculitis (AAV) lead to worse glucocorticoid-related toxicity. Although glucocorticoids remain the main adjunctive immunosuppression of AAV treatment, the narrow therapeutic window supports the need for glucocorticoids-sparing treatments, thus acting as a restraint for the market growth.

Key Players

Major players operating in the global ANCA vasculitis drug market include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca.

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).

Market Dynamics

Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual

Key features of the study:

  • This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ANCA vasculitis drug market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market

Detailed Segmentation:

  • Global ANCA Vasculitis Drug Market, By Type:
    • Granulomatosis with Polyangiitis (GPA) 
    • Microscopic Polyangiitis (MPA)  
    • Eosinophilic Granulomatosis with Polyangiitis (EGPA) 
    • Renal-limited Vasculitis
  • Global ANCA Vasculitis Drug Market, By Drug Type:
    • Glucocorticoids
    • Cyclophosphamide
    • Rituximab
    • Methotrexate
    • Mycophenolate mofetil
    • Azathioprine
    • Mepolizumab
    • Avacopan 
    • Others
  • Global ANCA Vasculitis Drug Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies 
  • Global ANCA Vasculitis Drug Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe  
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • ChemoCentryx, Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Vifor Pharma
    • GlaxoSmithKline plc
    • Amgen
    • Genentech, Inc.
    • Pfizer Inc.
    • Biogen
    • InflaRx GmbH
    • AstraZeneca

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global ANCA vasculitis drug market size is estimated to be valued at US$ 463.82 million in 2022 and is expected to exhibit a CAGR of 5.5% between 2022 and 2030.
Factors such as increasing approvals for ANCA vasculitis drugs by the regulatory bodies and increasing research and development activities by key players in market to develop ANCA vasculitis drugs are expected to drive the market growth.
Granulomatosis with Polyangiitis (GPA) is the leading type segment in the market.
The major factors hampering growth of the market include side effects associated with glucocorticoid use such as glucocorticoid toxicity.
Major players operating in the market include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo